Cell Genesys reports long term survival data in Phase II trial of GVAX prostate cancer vaccine

ORLANDO, FL, May 19, 2002Cell Genesys, Inc. (Nasdaq: CEGE) today reported encouraging long term survival data from a Phase II multicenter clinical trial of GVAX prostate cancer vaccine which demonstrates a dose-dependent trend toward prolonged survival in patients with hormone refractory prostate cancer metastatic to bone. In the 34-patient study, seven of 10 (70 percent) patients receiving the higher dose level of the vaccine are alive 2.5 years after treatment (median survival greater than 30 months). Of the 24 patients receiving the lower dose of the vaccine, nine of 22 patients (41 percent) are alive 2.5 years after treatment (median survival 22 months), and two were lost to follow-up. These results compare favorably to the reported median survival of seven to 11 months for hormone refractory prostate cancer patients with bone metastases who are treated with chemotherapy, the current standard of care for this patient group. The dose-dependent improvement in survival was consistent with a previously reported improvement in time to disease progression measured by both radiologic and prostate-specific antigen (PSA) endpoints also in favor of the high dose group. Treatment with GVAX vaccine was safe and well tolerated. These data were presented at the American Society of Clinical Oncology (ASCO) Meeting in Orlando, FL by Jonathan Simons, M.D., of Emory University.

The study reported at ASCO employed a six-month treatment regimen in which patients received an initial "priming" dose of GVAX prostate cancer vaccine followed by 12 biweekly "booster doses using either a high dose or threefold lower dose regimen. The two dose groups were comparable with respect to disease stage, duration and prior treatment for their prostate cancer as well as other demographic criteria. The vaccine, which is a non patient-specific, off-the-shelf product was administered by an intradermal injection into the skin of the arms and legs in an outpatient clinic setting. Patien

Contact: Claire Campbell
Feinstein Kean Healthcare

Page: 1 2 3 4

Related biology news :

1. Cell Genesys reports antitumor activity in Phase I/II GVAX lung cancer vaccine trial
2. UroGenesys researchers discover new target antigen for prostate cancers
3. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
4. Scientists question reports of massive ant supercolonies in California and Europe
5. Survey reports fall in stem cell transplants for breast cancer
6. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
7. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine
8. By the year 2050, human population could add 2.6 billion people, reports Rockefeller scientist
9. Measles on the rise as vaccinations fall in the UK, Science study reports
10. WCS biologist George Schaller reports surprising increase in Tibets wildlife
11. Clinical study reports findings of combination therapy with DOXIL

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: